Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis by Nathan R. Hill (802856)

“…CKD prevalence by stage was Stage-1 (eGFR>90+ACR>30): 3·5% (2·8–4·2%); Stage-2 (eGFR 60–89+ACR>30): 3·9% (2·7–5·3%); Stage-3 (eGFR 30–59): 7·6% (6·4–8·9%); Stage-4 = (eGFR 29–15): 0·4% (0·3–0·5%); and Stage-5 (eGFR<15): 0·1% (0·1–0·1%). …”

Tumor growth under different drugs. EGFR mutation is accounted for by increasing <i>λ</i>_<i>E</i> by factor 3. by Xiulan Lai (494041)

“…(b) Both anti-miR-21 and the gefitinib, a drug that inhibits the EGFR, reduce the growth of tumor; anti-miR-21 is accounted for by reducing <i>λ</i>_<i>m</i>₁ to <i>λ</i>_<i>m</i>₁/2, and EGFR-inhibitor gefitinib is accounted for by decreasing 3<i>λ</i>_<i>E</i> to 1.5<i>λ</i>_<i>E</i>. …”

Seedling phenotypes of plants expressing SAUR63:X fusion proteins. by Punita Nagpal (185838)

Hypocotyl and cotyledon phenotypes of plants expressing SAUR63:X fusion proteins. by Punita Nagpal (185838)

A close-up shot of protein-protein docking, from experiment to theory and reverse with the PROTAC performers by Khanh Quynh Thi Nguyen (17865389)

“…<p>PROTACs (Proteolysis Targeting Chimeras), heterobifunctional molecules, exhibit selectivity in degrading target proteins through E3 ubiquitin ligases. Designing effective PROTACs requires a deep understanding of the intricate binding interactions in the ternary complex (POI/PROTAC/E3 ligase), crucial for efficient target protein degradation. …”

Seedling phenotypes of plants expressing SAUR63:YFP:HA variants. by Punita Nagpal (185838)

Expression of HLA-DR and HLA-DP subunits. by Benedikt Hermann Siegler (5421062)

Effects of mutations on SAUR63 properties. by Punita Nagpal (185838)

MOLECULAR FEATURES OF TRIPLE NEGATIVE BREAST CANCER STEM CELLS: A GENE EXPRESSION PROFILING ANALYSIS OF MDA-MB-231 CELLS by Hourani, Shireen Bayan

“…Triple negative breast cancer (TNBC) is a chemoresistant subtype of female breast tumors. …”
Get full text

Data Sheet 7_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 6_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 1_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 3_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 8_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 4_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 5_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 2_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Colistin-stimulated ROS production is significantly impaired by the presence of colistin resistance-conferring proteins (EptA/MCR-1/ICR-Mo). by Wenhui Wei (176525)

“…<i>coli</i>. <b>E & F</b> Colistin-triggered production of hydrogen peroxide is decreased upon the expression of MCR-1 in <i>E</i>. …”

Table_1_Identification of cytochrome P450 gene family and functional analysis of HgCYP33E1 from Heterodera glycines.xls by Jia You (477131)

“…Compared to the control and dsGFP-treated group, silencing of HgCYP33E1 did not affect the J2 behaviors and the early invasion ability, while it decreased the number of J4s in soybean roots after 18-d inoculation with the dsHgCYP33E1-treated nematodes. …”

Model of the early stages of the olfactory system of the <i>Drosophila</i>. by Mario Pannunzi (553941)